Savara, Inc. (SVRA)

NASDAQ: SVRA · Delayed Price · USD
1.15
-0.07 (-5.74%)
At close: Jan 21, 2022 4:00 PM
1.14
-0.01 (-0.87%)
After-hours:Jan 21, 2022 5:51 PM EST
Market Cap130.95M
Revenue (ttm)1,000
Net Income (ttm)-45.45M
Shares Out113.87M
EPS (ttm)-0.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume356,569
Open1.21
Previous Close1.22
Day's Range1.13 - 1.22
52-Week Range1.03 - 3.58
Beta1.03
AnalystsStrong Buy
Price Target5.00 (+334.8%)
Earnings Daten/a

About SVRA

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

IndustryBiotechnology
CEORobert Neville
Employees27
Stock ExchangeNASDAQ
Ticker SymbolSVRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Savara stock is "Strong Buy." The 12-month stock price forecast is 5.00, which is an increase of 334.78% from the latest price.

Price Target
$5.00
(334.78% upside)
Analyst Consensus: Strong Buy

News

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...

2 weeks ago - Business Wire

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new em...

1 month ago - Business Wire

Savara to Participate in Two Upcoming Investor Healthcare Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...

2 months ago - Business Wire

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending...

2 months ago - Business Wire

Savara to Present at the Jefferies London Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the ...

2 months ago - Business Wire

Savara to Present at the Inaugural Piper Sandler Lung Day

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in ...

3 months ago - Business Wire

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new emp...

4 months ago - Business Wire

Savara Reports Second Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter endin...

5 months ago - Business Wire

3 Net Current Asset Value Stock Picks

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can make huge margins of return out of these stocks after the market h...

Other symbols:DSSGLTO
6 months ago - GuruFocus

Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

6 months ago - Zacks Investment Research

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the ...

6 months ago - Business Wire

Implied Volatility Surging for Savara (SVRA) Stock Options

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Savara to Present at the Jefferies Virtual Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at ...

7 months ago - Business Wire

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at ...

8 months ago - Business Wire

Savara Reports First Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending...

8 months ago - Business Wire

Penny Stocks To Buy According To Analysts With Price Targets Up to 341%

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...

Other symbols:EVGNPAVMSYBX
9 months ago - PennyStocks

7 Reddit Penny Stocks to Buy for a Biotech Boom

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

9 months ago - InvestorPlace

7 Penny Stocks with Interesting Catalysts

While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on Inv...

Other symbols:ELYSRFILVRME
9 months ago - InvestorPlace

7 Reddit Penny Stocks to Keep Your Eye on for Big Movement

Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.

Other symbols:LPCNOGISNDLYVRZOMZSAN
9 months ago - InvestorPlace

7 Reddit Penny Stocks Seeing the Most Chatter Today

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...

10 months ago - InvestorPlace

Do Options Traders Know Something About Savara (SVRA) Stock We Don't?

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Savara Stock Rallies: Technical Analysis Levels

Savara Inc. (NASDAQ:SVRA) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target.

10 months ago - Benzinga

Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' Option

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of i...

10 months ago - Business Wire

Savara Announces Pricing of Public Offering of Common Stock

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a p...

10 months ago - Business Wire

Savara Announces Proposed Public Offering of Common Stock

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in...

10 months ago - Business Wire